Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 5/20 | 0.32 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2951930 | 0.94 | L3MBTL1 (0.40) | L3MBTL1TLR8KDRSMPD1 | |
| SCHEMBL7338253 | 0.92 | KDR (0.40) | L3MBTL1KDRSMPD1 | |
| SCHEMBL2384675 | 0.92 | KDR (0.40) | L3MBTL1KDRSMPD1 | |
| SCHEMBL17943855 | 0.92 | KDR (0.40) | L3MBTL1KDRSMPD1 | |
| SCHEMBL671590 | 0.88 | — | — | |
| SCHEMBL5016729 | 0.80 | CSNK2A2 (0.33) | L3MBTL1 | |
| SCHEMBL13605810 | 0.79 | JAK2 (0.35) | L3MBTL1ALDH1A1KMT2ABTK | |
| SCHEMBL1581682 | 0.79 | — | — | |
| SCHEMBL19438830 | 0.78 | HEXA (0.30) | — | |
| SCHEMBL6724293 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466028-B2 | Fused 1,4-oxazepines as BET protein degraders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-10-11 | — | — | US | disclosed |
| US-9707205-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2017-07-18 | — | — | US | disclosed |
| EP-2344484-B1 | S1P RECEPTORS MODULATORS AND USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2016-06-08 | — | — | EP | disclosed |
| US-20160038455-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD. (AU) | 2016-02-11 | — | — | US | disclosed |
| US-9193716-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2015-11-24 | — | — | US | disclosed |
| WO-2014063199-A1 | ORGANIC COMPOUNDS | AKAAL PHARMA PTY LTD (AU) | 2014-05-01 | — | — | WO | disclosed |
| US-20140066427-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD. (AU) | 2014-03-06 | — | — | US | disclosed |
| US-8592399-B2 | S1P receptors modulators and their use thereof | AKAAL PHARMA PTY LTD. (AU) | 2013-11-26 | — | — | US | disclosed |
| EP-2411388-A2 | PROCESS FOR THE PRODUCTION OF FUSED, TRICYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110318388-A1 | S1P Receptors Modulators and Their Use Thereof | AKAAL PHARMA PTY LTD (AU) | 2011-12-29 | — | — | US | disclosed |
| CN-102186845-A | S1p receptors modulators and their use thereof | AKAAL PHARMA PTY LTD | 2011-09-14 | — | — | CN | disclosed |
| EP-2344484-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | Akaal Pharma Pty Ltd (AU) | 2011-07-20 | — | — | EP | disclosed |
| WO-2010043000-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | AKAAL PHARMA PTY LTD (AU) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038455-A1 | S1P RECEPTORS MODULATORS AND THEIR USE THEREOF | S1PR1, S1PR5, S1PR2 | L3MBTL1 3695/4885ALDH1A1 3172/4885POLB 4531/4885 |
| US-11466028-B2 | Fused 1,4-oxazepines as BET protein degraders | BRD4, BET1, BRD1 | L3MBTL1 534/4885ALDH1A1 2770/4885POLB 610/4885 |
| US-20110318388-A1 | S1P Receptors Modulators and Their Use Thereof | S1PR1, S1PR5, S1PR2 | L3MBTL1 3695/4885ALDH1A1 3172/4885POLB 4531/4885 |
| US-20140066427-A1 | S1P Receptors Modulators and Their Use Thereof | S1PR1, S1PR2, S1PR5 | L3MBTL1 4256/4885ALDH1A1 3392/4885POLB 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.